<?xml version="1.0" encoding="UTF-8"?>
<title-group>
 <article-title>Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol</article-title>
</title-group>
